You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with r…

Citation Tools

Article menu

Download PDFPDF

Oral Presentations
Immunogenicity of biologics; myth or reality?
OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kay J, Weinblatt M, Keystone E, et al
OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases 2017;76:136.